Everolimus

Advance Directives, Steroid therapy, Carcinoid Tumor + 11 more

Treatment

22 FDA approvals

0 Active Studies for Everolimus

What is Everolimus

Everolimus

The Generic name of this drug

Treatment Summary

Everolimus is a drug that works like Rapamycin, an immunosuppressant used to help prevent organ transplant rejection. It stops the mTORC1 protein from working, but does not affect the mTORC2 protein.

Afinitor

is the brand name

image of different drug pills on a surface

Everolimus Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Afinitor

Everolimus

2009

59

Approved as Treatment by the FDA

Everolimus, also known as Afinitor, is approved by the FDA for 22 uses including Kidney Transplant Rejection and unresectable gastrointestinal origin Progressive Neuroendocrine Tumors .

Kidney Transplant Rejection

Used to treat Kidney Transplant Rejection in combination with Basiliximab

unresectable gastrointestinal origin Progressive Neuroendocrine Tumors

Subependymal giant cell astrocytoma, tuberous sclerosis complex

locally advanced lung origin Progressive Neuroendocrine Tumors

Tuberous Sclerosis

Neuroendocrine Tumors

Tuberous Sclerosis

Lung

metastatic lung origin Progressive Neuroendocrine Tumors

pancreatic origin Progressive Neuroendocrine Tumors

Liver Transplant Rejection

Used to treat Liver Transplant Rejection in combination with Tacrolimus

metastatic gastrointestinal origin Progressive Neuroendocrine Tumors

unresectable lung origin Progressive Neuroendocrine Tumors

locally advanced gastrointestinal origin Progressive Neuroendocrine Tumors

Advance Directives

Used to treat refractory, advanced Breast cancer in combination with Exemestane

Renal angiomyolipoma, tuberous sclerosis complex

refractory Advanced Renal Cell Carcinoma

Neuroendocrine Tumors

Neoplasm Metastasis

Neuroendocrine Tumors

Steroid therapy

Used to treat Steroid therapy in combination with Tacrolimus

Neuroendocrine Tumors

Effectiveness

How Everolimus works in the body

Everolimus is a drug that targets the mTOR protein, which helps control cell growth and division. By blocking the mTOR protein, Everolimus stops cells from dividing and growing, which can stop cancer cells from spreading. It also prevents new blood vessels from forming, which starves the cancer cells of oxygen and nutrients. Finally, it reduces the amount of glucose (sugar) that cancer cells can take in, further starving them of energy.

When to interrupt dosage

The proposed measure of Everolimus is contingent upon the marked condition, including metastatic lung origin Progressive Neuroendocrine Tumors, Heart and Advance Directives. The quantity likewise fluctuates as per the approach of delivery (e.g. Tablet or Oral) featured in the table beneath.

Condition

Dosage

Administration

Advance Directives

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Steroid therapy

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Carcinoid Tumor

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Tuberous Sclerosis

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Tuberous Sclerosis

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Waldenstrom Macroglobulinemia

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

refractory Advanced Renal Cell Carcinoma

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Neoplasm Metastasis

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Neuroendocrine Tumors

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Neuroendocrine Tumors

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

pancreatic origin Progressive Neuroendocrine Tumors

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Neuroendocrine Tumors

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Lung

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Neuroendocrine Tumors

2.0 mg, , 3.0 mg, 5.0 mg, 10.0 mg, 2.5 mg, 0.25 mg, 0.5 mg, 0.75 mg, 7.5 mg, 1.0 mg

Tablet, for suspension, Oral, Tablet, for suspension - Oral, , Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Everolimus.

Common Everolimus Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Everolimus is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Everolimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Everolimus.

Abetimus

Major

The risk or severity of adverse effects can be increased when Everolimus is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Everolimus is combined with Acteoside.

Everolimus Toxicity & Overdose Risk

The drug is toxic at 0.63 nanomolar concentrations.

image of a doctor in a lab doing drug, clinical research

Everolimus Novel Uses: Which Conditions Have a Clinical Trial Featuring Everolimus?

16 active clinical trials are currently in progress to assess the potential of Everolimus in providing advanced treatment of locally advanced lung origin Progressive Neuroendocrine Tumors, advanced Carcinoid tumor and Heart ailments.

Condition

Clinical Trials

Trial Phases

pancreatic origin Progressive Neuroendocrine Tumors

0 Actively Recruiting

Steroid therapy

0 Actively Recruiting

Carcinoid Tumor

0 Actively Recruiting

Tuberous Sclerosis

0 Actively Recruiting

Advance Directives

0 Actively Recruiting

refractory Advanced Renal Cell Carcinoma

0 Actively Recruiting

Tuberous Sclerosis

0 Actively Recruiting

Neuroendocrine Tumors

0 Actively Recruiting

Neuroendocrine Tumors

0 Actively Recruiting

Neuroendocrine Tumors

0 Actively Recruiting

Neuroendocrine Tumors

0 Actively Recruiting

Waldenstrom Macroglobulinemia

0 Actively Recruiting

Neoplasm Metastasis

0 Actively Recruiting

Lung

0 Actively Recruiting

Everolimus Reviews: What are patients saying about Everolimus?

4

Patient Review

12/22/2014

Everolimus for Prevention of Liver Transplant Rejection

I was using this as an anti-rejection medication for my liver transplant, and it also worked well as a chemo drug against a tumor that developed in my old liver. The only issues I had were a canker sore (which was easily treated), some swelling in one lower leg (treated with lymphodema massage), and a few skin bumps/boils. I continued to use Prograf in addition to Zortress.

2

Patient Review

1/27/2012

Everolimus for Cancer Involving the Kidney Cells

On the ninth day after starting this treatment, I developed severe mouth sores.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about everolimus

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is everolimus a chemotherapy?

"Everolimus works by inhibiting the growth of cancer cells.

Everolimus is a chemotherapy drug that stops cancer cells from growing. It is a type of drug called an "mTOR kinase inhibitor.""

Answered by AI

How long can you take everolimus?

"You should take everolimus every day for as long as it keeps working or until you experience unacceptable side effects. It is a long-term treatment. In clinical trials, people took the average for 24.0 weeks (range one week to almost 200 weeks)."

Answered by AI

What is the drug everolimus used for?

"Everolimus is a medication that is used to treat late-stage cancers, noncancerous tumors, such as kidney and breast cancer, subependymal giant cell astrocytoma (SEGA, a brain tumor), renal angiomyolipoma (kidney tumor), partial-onset seizures (epilepsy) with tuberous sclerosis complex (TSC), and neuroendocrine tumors."

Answered by AI

What are the side effects of everolimus?

"The following are symptoms of something wrong: bloating or swelling of the face, arms, hands, lower legs, or feet; bloody nose; chest pain or tightness; decreased weight; difficult or labored breathing; difficulty with swallowing; sores, ulcers, or white spots on the lips, tongue, or inside the mouth; tingling of the hands or feet."

Answered by AI